Insulin kinetics in type-1 diabetes: continuous and bolus delivery of rapid acting insulin

We investigated insulin lispro kinetics with bolus and continuous subcutaneous insulin infusion (CSII) modes of insulin delivery. Seven subjects with type-1 diabetes treated by CSII with insulin lispro have been studied during prandial and postprandial conditions over 12 hours. Eleven alternative models of insulin kinetics have been proposed implementing a number of putative characteristics. We assessed 1) the effect of insulin delivery mode, i.e., bolus or basal, on the insulin absorption rate, the effects of 2) insulin association state and 3) insulin dose on the rate of insulin absorption, 4) the remote insulin effect on its volume of distribution, 5) the effect of insulin dose on insulin disappearance, 6) the presence of insulin degradation at the injection site, and finally 7) the existence of two pathways, fast and slow, of insulin absorption. An iterative two-stage parameter estimation technique was used. Models were validated through assessing physiological feasibility of parameter estimates, posterior identifiability, and distribution of residuals. Based on the principle of parsimony, best model to fit our data combined the slow and fast absorption channels and included local insulin degradation. The model estimated that 67(53-82)% [mean (interquartile range)] of delivered insulin passed through the slow absorption channel [absorption rate 0.011(0.004-0.029) min/sup -1/] with the remaining 33% passed through the fast channel [absorption rate 0.021(0.011-0.040) min/sup -1/]. Local degradation rate was described as a saturable process with Michaelis-Menten characteristics [V/sub MAX/=1.93(0.62-6.03) mU min/sup -1/, K/sub M/=62.6(62.6-62.6) mU]. Models representing the dependence of insulin absorption rate on insulin disappearance and the remote insulin effect on its volume of distribution could not be validated suggesting that these effects are not present or cannot be detected during physiological conditions.

[1]  J F Boisvieux,et al.  Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. , 1984, Drug metabolism reviews.

[2]  C. Binder Absorption of injected insulin. A clinical-pharmacological study. , 2009, Acta pharmacologica et toxicologica.

[3]  Ewart R. Carson,et al.  The mathematical modeling of metabolic and endocrine systems : model formulation, identification, and validation , 1983 .

[4]  D Rodbard,et al.  Computer Simulation of Plasma Insulin and Glucose Dynamics After Subcutaneous Insulin Injection , 1989, Diabetes Care.

[5]  G. Schwarz Estimating the Dimension of a Model , 1978 .

[6]  R. Hovorka,et al.  Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. , 2004, Physiological measurement.

[7]  O. Faber,et al.  Variation in125i-insulin absorption and blood glucose concentration , 1979, Diabetologia.

[8]  M. Shichiri,et al.  Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas. , 1997, Frontiers of medical and biological engineering : the international journal of the Japan Society of Medical Electronics and Biological Engineering.

[9]  Frost Dp,et al.  The kinetics of insulin metabolism in diabetes mellitus. , 1973 .

[10]  P. Felig,et al.  Alterations in Insulin Absorption and in Blood Glucose Control Associated with Varying Insulin Injection Sites in Diabetic Patients , 1980, Annals of Internal Medicine.

[11]  E. Lightfoot,et al.  A model for multiple subcutaneous insulin injections developed from individual diabetic patient data. , 1995, The American journal of physiology.

[12]  E. Kraegen,et al.  Insulin responses to varying profiles of subcutaneous insulin infusion: kinetic modelling studies , 1984, Diabetologia.

[13]  D Rodbard,et al.  A pharmacodynamic approach to optimizing insulin therapy. , 1991, Computer methods and programs in biomedicine.

[14]  D. Owens,et al.  Human Insulin: Clinical Pharmacological Studies in Normal Man , 1986 .

[15]  T. Deckert,et al.  Clinical Factors Influencing the Absorption of 125I-NPH Insulin in Diabetic Patients , 1983, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[16]  R. DeFronzo,et al.  Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. , 1983, The American journal of physiology.

[17]  P. Sejrsen,et al.  Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients. , 1985, Scandinavian journal of clinical and laboratory investigation.

[18]  G. Slama,et al.  Influence of concentration on the kinetics of SC-infused insulin. Comparison between square-wave SC infusion and bolus SC injection. , 1985, Metabolism: clinical and experimental.

[19]  T. Kobayashi,et al.  The Pharmacokinetics of Insulin After Continuous Subcutaneous Infusion or Bolus Subcutaneous Injection in Diabetic Patients , 1983, Diabetes.

[20]  H. Akaike A new look at the statistical model identification , 1974 .

[21]  D R Owens,et al.  Subcutaneous Insulin Absorption Explained by Insulin's Physicochemical Properties: Evidence From Absorption Studies of Soluble Human Insulin and Insulin Analogues in Humans , 1991, Diabetes Care.

[22]  Remo Guidieri Res , 1995, RES: Anthropology and Aesthetics.

[23]  J Seydoux,et al.  Absorption kinetics of subcutaneously injected insulin , 1979, Diabetologia.

[24]  K. Tranberg Hepatic uptake of insulin in man. , 1979, The American journal of physiology.

[25]  W. Duckworth,et al.  Accelerated Insulin Degradation: An Alternate Mechanism for Insulin Resistance , 1979, Diabetes Care.

[26]  Christian Binder,et al.  Modeling absorption kinetics of subcutaneous injected soluble insulin , 1989, Journal of Pharmacokinetics and Biopharmaceutics.

[27]  P. Sönksen,et al.  A comparative study on the metabolism of human insulin and porcine proinsulin in man. , 1973, Clinical science and molecular medicine.

[28]  P Vicini,et al.  The iterative two-stage population approach to IVGTT minimal modeling: improved precision with reduced sampling. Intravenous glucose tolerance test. , 2001, American journal of physiology. Endocrinology and metabolism.

[29]  Z Trajanoski,et al.  Pharmacokinetic Model for the Absorption of Subcutaneously Injected Soluble Insulin and Monomeric Insulin - Analogues - Pharmakokinetisches Modell für die Absorption von subkutan injiziertem löslichem Insulin und monomeren Insulinanaloga , 1993, Biomedizinische Technik. Biomedical engineering.

[30]  R. Hovorka Chapter 5 – Parameter Estimation , 2001 .

[31]  O Faber,et al.  Insulin Pharmacokinetics , 1984, Diabetes Care.

[32]  V. Jörgens,et al.  Absorption Kinetics and Biologic Effects of Subcutaneously Injected Insulin Preparations , 1982, Diabetes Care.

[33]  Reinder Evertz,et al.  Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia. , 2002, Diabetes.

[34]  Claudio Cobelli,et al.  Models of subcutaneous insulin kinetics. A critical review , 2000, Comput. Methods Programs Biomed..

[35]  D. Owens,et al.  Comparison of Subcutaneous Soluble Human Insulin and Insulin Analogues (AspB9, GluB27; AspB10; AspB28) on Meal-Related Plasma Glucose Excursions in Type I Diabetic Subjects , 1991, Diabetes Care.

[36]  D R Owens,et al.  Absorption Kinetics and Action Profiles of Subcutaneously Administered Insulin Analogues (AspB9GluB27, AspB10, AspB28) in Healthy Subjects , 1991, Diabetes Care.